WHO Drops Hydroxychloroquine and Lopinavir/Ritonavir Arms from Solidarity Trial Following Interim Results

The World Health Organization has officially accepted a recommendation from the International Steering Committee of the Solidarity Trial to immediately discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir treatment arms. The landmark Solidarity Trial was established by the global health body early in the course of the pandemic to find an effective, life-saving COVID-19 treatment specifically tailored for hospitalized patients fighting severe forms of the disease.

The International Steering Committee formulated this crucial recommendation in light of compelling new evidence gathered during the trial. Specifically, the decision was based on interim results comparing hydroxychloroquine against the standard-of-care, and lopinavir/ritonavir against the standard-of-care. Furthermore, the committee conducted a comprehensive review of all available evidence from various global trials that had been presented during the recent WHO Summit on COVID-19 research and innovation, held on July 1-2.

The interim trial results clearly demonstrate that both hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality rates of hospitalized COVID-19 patients when compared directly against patients receiving only the standard-of-care protocols. In response to these sobering findings, Solidarity trial investigators across participating centers have been instructed to interrupt the trials involving these two specific therapeutic arms with immediate effect.

Despite the lack of efficacy regarding mortality reduction, the interim results do not provide solid, definitive evidence of increased mortality directly caused by either of the two drugs. However, researchers did note some associated safety signals that emerged during the analysis of clinical laboratory findings from the add-on Discovery trial, which operates as a closely integrated participant within the broader framework of the Solidarity trial. These noteworthy safety signals and their detailed laboratory implications will be formally documented and reported in the upcoming peer-reviewed publication of the trial’s interim findings.

WHO officials have emphasized that this momentous decision applies strictly and exclusively to the conduct of the Solidarity trial in hospitalized patients. The discontinuation does not affect or invalidate the possible evaluation in other separate studies examining hydroxychloroquine or lopinavir/ritonavir in non-hospitalized patient populations, nor does it impact their potential assessment as pre-exposure or post-exposure prophylaxis measures for COVID-19 prevention. As the scientific community processes these developments, the comprehensive interim results of the Solidarity trial are currently being prepared for formal peer-reviewed publication to ensure total transparency and to guide future global research priorities. Daniela Bagozzi, Senior Information Officer, noted the significance of the findings as the organization continues its worldwide quest for effective COVID-19 therapeutics.

Share:

rifanmuazin writes for Stepping Stones Center.